Show simple item record

dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional
dc.contributor.advisorGrillo Ardila, Carlos Fernando
dc.contributor.authorMartínez Moncayo, Deicy Bibiana
dc.date.accessioned2022-02-11T20:06:51Z
dc.date.available2022-02-11T20:06:51Z
dc.date.issued2021-12-15
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/80953
dc.descriptionilustraciones, gráficas, tablas
dc.description.abstractSe estima que el tabaco es responsable de 8 millones muertes al año al rededor del mundo, no solo como consecuencia directa de su consumo, sino también como resultado del perjuicio que produce la exposición pasiva a este agente o sus derivados (1 millón de muertes al año). El consumo de tabaco también repercute negativamente sobre la calidad de vida y las condiciones de salud de población vulnerable (v.g. menores de edad, población carcelaria y mujeres gestantes). El tabaquismo en el embarazo es la primera causa prevenible de parto pretérmino y bajo peso al nacer. Los medicamentos que se usan comúnmente para ayudar a las personas a dejar de fumar incluyen la terapia de reemplazo de nicotina, bupropión y vareniclina. Algunas personas que fuman también usan cigarrillos electrónicos que contienen nicotina para evitar fumar. No obstante, las recomendaciones sobre el manejo farmacológico y no farmacológico en mujeres embarazadas son amplias y heterogéneas; actualmente existen múltiples intervenciones farmacológicas disponibles, que buscan apoyar el cese del consumo de tabaco durante la gestación y aunque la abstinencia al principio del embarazo genera mayores beneficios para el feto y la madre, dejar de fumar en cualquier momento durante el curso de la gestación genera un impacto favorable[22] el cual se encuentra demarcado en una reducción significativa de un 20% en el riesgo de presentar resultados perinatales adversos [27]. Conviene entonces que el especialista en Obstetricia y Ginecología conozca la evidencia disponible en torno a la seguridad y la efectividad de las diferentes intervenciones farmacológicas disponibles, que apoyan el cese del consumo de tabaco durante la gestación. (Texto tomado de la fuente).
dc.description.abstractIt is estimated that tobacco is responsible for 8 million deaths a year around the world, not only as a direct consequence of its consumption, but also as a result of the damage caused by passive exposure to this agent or its derivatives (1 million deaths to anus). Tobacco use also has a negative impact on the quality of life and health conditions of the vulnerable population (e.g. minors, prison population and pregnant women). Smoking in pregnancy is the leading preventable cause of preterm labor and low birth weight. Medications commonly used to help people quit smoking include nicotine replacement therapy, bupropion, and varenicline. Some smokers also use e-cigarettes that contain nicotine to help avoid smoking. However, the recommendations on pharmacological and non-pharmacological management in pregnant women are broad and heterogeneous; Currently there are multiple pharmacological interventions available, which seek to support the cessation of tobacco consumption during pregnancy and although abstinence in early pregnancy generates greater benefits for the fetus and the mother, stopping smoking at any time during the course of pregnancy generates a favorable impact [22] which is demarcated in a significant reduction of 20% in the risk of presenting adverse perinatal outcomes [27]. It is therefore advisable for the specialist in Obstetrics and Gynecology to know the available evidence regarding the safety and effectiveness of the different pharmacological interventions available, which support the cessation of tobacco consumption during pregnancy.
dc.format.extentxv, 63 páginas
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.publisherUniversidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subject.ddc610 - Medicina y salud::618 - Ginecología, obstetricia, pediatría, geriatría
dc.titleIntervenciones farmacológicas para el cese del consumo de tabaco en población gestante. Revisión sistemática de revisiones sistemáticas
dc.typeTrabajo de grado - Especialidad Médica
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Especialidad en Obstetricia y Ginecología
dc.description.degreelevelEspecialidades Médicas
dc.description.degreenameEspecialista en Obstetricia y Ginecología
dc.description.methodsRevisión sistemática de revisiones sistemáticas. Se incluirán revisiones sistemáticas metaanálisis que incluyan estudios que evalúen desenlaces clínicos maternos y neonatales posterior a las diferentes intervenciones farmacológicas.
dc.identifier.instnameUniversidad Nacional de Colombia
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourlhttps://repositorio.unal.edu.co/
dc.publisher.departmentDepartamento de Obstetricia y Ginecología
dc.publisher.facultyFacultad de Medicina
dc.publisher.placeBogotá, Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.indexedBireme
dc.relation.references1. Jesús Mardomingo Sanz M. Protocolos de la Asociación Española de Psiquiatría Infanto-Juvenil.
dc.relation.references2. Jha P, Peto R. Global Effects of Smoking, of Quitting, and of Taxing Tobacco. New England Journal of Medicine. 2014;370:60–8.
dc.relation.references3. West R. Tobacco smoking: Health impact, prevalence, correlates and interventions.
dc.relation.references4. Durán* EPT-JF. Hoja Informativa tabaco 2019. Subdirección de Investigación, Vigilancia Epidemiológica, Promoción y Prevención Instituto Nacional de Cancerología ESE. 2019;:1–2.
dc.relation.references5. Ministerio de salud. Resultados Encuesta Nacional Tabaquismo en Jóvenes. Ministerio de salud. 2018;:44
dc.relation.references6. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. Journal of the American College of Cardiology. 2004;43:1731–7.
dc.relation.references7. Peña E, Osorio D, Gamboa Ó, Caporale J, Augustovski F, Alcaraz A, et al. Carga de enfermedad atribuible al uso de tabaco en Colombia y potenciales beneficios sanitarios y económicos del aumento del precio del cigarrillo mediante impuestos. Revista Colombiana de Cancerología. 2019;23:135–43.
dc.relation.references8. Muthukrishnan A, Warnakulasuriya S. Oral health consequences of smokeless tobacco use. Indian Journal of Medical Research, Supplement. 2018;148:35–40.
dc.relation.references9. Prignot J. Quantification and chemical markers of tobacco-exposure. European Journal of Respiratory Diseases. 1987;70:1–7.
dc.relation.references10. Center for Disease Control and Prevention. NHIS - Adult Tobacco Use - Glossary. Adult Tobacco use Information. 2017
dc.relation.references11. P A, JC P, A R, A D, I H, I A-A, et al. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis. 2013;28:323–31. doi:10.1093/MUTAGE/GET008
dc.relation.references12. Qiu F, Liang CL, Liu H, Zeng YQ, Hou S, Huang S, et al. Impacts of cigarette smoking on immune responsiveness: Up and down or upside down? Oncotarget. 2017;8:268–84
dc.relation.references13. Hecht SS. Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute. 1999;91:1194–210.
dc.relation.references14. L L, M L, X W. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. DNA repair. 2020;88. doi:10.1016/J.DNAREP.2020.102785.
dc.relation.references15. Holloway AC, Salomon A, Soares MJ, Garnier V, Raha S, Sergent F, et al. Characterization of the adverse effects of nicotine on placental development: in vivo and in vitro studies. American Journal of Physiology - Endocrinology and Metabolism. 2014;306:E443. doi:10.1152/AJPENDO.00478.2013.
dc.relation.references16. Blumenthal I. Carbon monoxide poisoning. Journal of the Royal Society of Medicine. 2001;94:270. doi:10.1177/014107680109400604.
dc.relation.references17. Lange S, Probst C, Rehm J, Popova S. National, regional, and global prevalence of smoking during pregnancy in the general population: a systematic review and meta-analysis. The Lancet Global Health. 2018;6:e769–76.
dc.relation.references18. Cortés-Yepes H. PREVALENCIA DE TABAQUISMO EN UNA POBLACIÓN DE EMBARAZADAS EN EL HOSPITAL UNIVERSITARIO SAN VICENTE DE PAÚL EN MEDELLíN (COLOMBIA). Revista Colombiana de Obstetricia y Ginecología. 2011;62:127–30.
dc.relation.references19. Poletta FA, López-Camelo JS, Gili JA, Montalvo G, Castilla EE, Del Estudio R. Consumo y exposición al humo de tabaco en mujeres embarazadas de Ecuador. Rev Panam Salud Publica. 27:2010.
dc.relation.references20. Ebert LM, Fahy K. Why do women continue to smoke in pregnancy? Women and Birth. 2007;20:161–8.
dc.relation.references21. Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database of Systematic Reviews. 2020;2020.
dc.relation.references22. Ioakeimidis N, Vlachopoulos C, Katsi V, Tousoulis D. Smoking cessation strategies in pregnancy: Current concepts and controversies. Hellenic Journal of Cardiology. 2019;60:11–5.
dc.relation.references23. Pineles BL, Park E, Samet JM. Systematic review and meta-analysis of miscarriage and maternal exposure to tobacco smoke during pregnancy. American Journal of Epidemiology. 2014;179:807–23.
dc.relation.references24. Pineles BL, Hsu S, Park E, Samet JM. Systematic review and meta-analyses of perinatal death and maternal exposure to tobacco smoke during pregnancy. American Journal of Epidemiology. 2016;184:87–97.
dc.relation.references25. Salmasi G, Grady R, Jones J, McDonald SD. Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Acta obstetricia et gynecologica Scandinavica. 2010;89:423–41.
dc.relation.references26. Polanska K, Krol A, Merecz-Kot D, Ligocka D, Mikolajewska K, Mirabella F, et al. Environmental tobacco smoke exposure during pregnancy and child neurodevelopment. International Journal of Environmental Research and Public Health. 2017;14.
dc.relation.references27. Soneji S, Beltrán-Sánchez H. Association of Maternal Cigarette Smoking and Smoking Cessation With Preterm Birth. JAMA network open. 2019;2:e192514.
dc.relation.references28. Giulietti F, Filipponi A, Rosettani G, Giordano P, Iacoacci C, Spannella F, et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Pressure & Cardiovascular Prevention. 2020;27:349. doi:10.1007/S40292-020-00396-9.
dc.relation.references29. P T, J M, M W. Pharmacokinetics and metabolism of nicotine. Pharmacological reports : PR. 2005;57:143–53. https://pubmed.ncbi.nlm.nih.gov/15886412/. Accessed 1 Sep 2021.
dc.relation.references30. Sailer S, Sebastiani G, Andreu-Férnández V, García-Algar O. Impact of nicotine replacement and electronic nicotine delivery systems on fetal brain development. International Journal of Environmental Research and Public Health. 2019;16.
dc.relation.references31. IM F, AC E, N G, M M, MF S, EK R. Nicotine pharmacokinetics of electronic cigarettes: A review of the literature. Regulatory toxicology and pharmacology : RTP. 2018;100:25–34. doi:10.1016/J.YRTPH.2018.09.004.
dc.relation.references32. Bowker K, Lewis S, Coleman T, Cooper S. Changes in the rate of nicotine metabolism across pregnancy: A longitudinal study. Addiction. 2015;110:1827–32.
dc.relation.references33. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2019;2019.
dc.relation.references34. Pernia S, DeMaagd G. The New Pregnancy and Lactation Labeling Rule. Pharmacy and Therapeutics. 2016;41:713. /pmc/articles/PMC5083079/. Accessed 18 Sep 2021.
dc.relation.references35. Perkins KA, Karelitz JL, Boldry MC. Reinforcement Enhancing Effects of Nicotine Via Patch and Nasal Spray. Nicotine & Tobacco Research. 2019;21:778. doi:10.1093/NTR/NTY038.
dc.relation.references36. MG K, AM AH. Varenicline. Profiles of drug substances, excipients, and related methodology. 2012;37:389–411. doi:10.1016/B978-0-12-397220-0.00010-6.
dc.relation.references37. Ne H, Faessel M, Obach RS, Rollema H, Ravva P, Williams KE, et al. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation.
dc.relation.references38. Varenicline. Drugs and Lactation Database (LactMed). 2021. https://www.ncbi.nlm.nih.gov/books/NBK501688/. Accessed 18 Sep 2021.
dc.relation.references39. Tran DT, Preen DB, Einarsdottir K, Kemp-Casey A, Randall D, Jorm LR, et al. Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. BMC Medicine. 2020;18. doi:10.1186/S12916-019-1472-9
dc.relation.references40. LM M, GA D, E C, A S, LC C, M H, et al. Spontaneous preterm birth and small for gestational age infants in women who stop smoking early in pregnancy: prospective cohort study. BMJ (Clinical research ed). 2009;338:1552. doi:10.1136/BMJ.B1081.
dc.relation.references41. S S, H B-S. Association of Maternal Cigarette Smoking and Smoking Cessation With Preterm Birth. JAMA network open. 2019;2. doi:10.1001/JAMANETWORKOPEN.2019.2514.
dc.relation.references42. Varenicline Pregnancy Cohort Study - Study Results - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/results/NCT01290445. Accessed 10 Oct 2021.
dc.relation.references43. P T, D V, RJ C, NL B. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction (Abingdon, England). 2019;114:1951–69. doi:10.1111/ADD.14721.
dc.relation.references44. A E, S R. Smoking in pregnancy and lactation: a review of risks and cessation strategies. European journal of clinical pharmacology. 2009;65:325–30. doi:10.1007/S00228-008-0609-0
dc.relation.references45. Jeong SH, Newcombe D, Sheridan J, Tingle M. Pharmacokinetics of cytisine, an α4β2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Testing and Analysis. 2015;7:475–82.
dc.relation.references46. Karnieg T, Wang X. Cytisine for smoking cessation. CMAJ. 2018;190:E596.
dc.relation.references47. Vaporizers, E-Cigarettes, and other Electronic Nicotine Delivery Systems (ENDS) | FDA. https://www.fda.gov/tobacco-products/products-ingredients-components/vaporizers-e-cigarettes-and-other-electronic-nicotine-delivery-systems-ends. Accessed 14 Oct 2021
dc.relation.references48. Khan SR, Berendt RT, Ellison CD, Ciavarella AB, Asafu-Adjaye E, Khan MA, et al. Bupropion Hydrochloride. In: Profiles of Drug Substances, Excipients and Related Methodology. Academic Press Inc.; 2016. p. 1–30
dc.relation.references49. Fokina VM, Xu M, Rytting E, Abdel-Rahman SZ, West H, Oncken C, et al. Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. Drug Metabolism and Disposition. 2016;44:1832. doi:10.1124/DMD.116.071530.
dc.relation.references50. SR K, RT B, CD E, AB C, E A-A, MA K, et al. Bupropion Hydrochloride. Profiles of drug substances, excipients, and related methodology. 2016;41:1–30. doi:10.1016/BS.PODRM.2015.12.001.
dc.relation.references51. JA C, JG M, BR H, IS C, JM S, AM W. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiology and drug safety. 2007;16:474–84. doi:10.1002/PDS.1296.
dc.relation.references52. Higgins G. Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training. Handbook. 2011;:649. https://training.cochrane.org/handbook/current. Accessed 31 May 2021
dc.relation.references53. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2019.
dc.relation.references54. Ferreira González I, Urrútia G, Alonso-Coello P. Revisiones sistemáticas y metaanálisis: bases conceptuales e interpretación. Revista Espanola de Cardiologia. 2011;64:688–96
dc.relation.references55. García-Perdomo HA. Evidence synthesis and meta-analysis: A practical approach. International Journal of Urological Nursing. 2016;10:30–6
dc.relation.references56. Arias MM. Lectura crítica en pequeñas dosis. 2015;:185–8.
dc.relation.references57. Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Journal of Clinical Epidemiology. 2016;69:225–34.
dc.relation.references58. Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE Handbook | Cochrane Training. the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Handbook. 2013. https://training.cochrane.org/resource/grade-handbook. Accessed 11 Apr 2021
dc.relation.references59. Shea BJ y col. BMJ. AMSTAR-2: herramienta de evaluación crítica de revisiones sistemáticas de estudios de intervenciones de salud. Vol. 21. No 1. Evidencia: 2018.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.decsCese del Hábito de Fumar
dc.subject.decsSmoking Cessation
dc.subject.decsMujeres Embarazadas
dc.subject.decsPregnant Women
dc.subject.decsRevisión Sistemática
dc.subject.decsSystematic Review
dc.subject.lembMedicamentos
dc.subject.lembDrugs
dc.subject.proposalTabaquismo
dc.subject.proposalEmbarazo
dc.subject.proposalPuerperio
dc.subject.proposalAbandono del habito tabáquico
dc.subject.proposalSmoking
dc.subject.proposalPregnancy
dc.subject.proposalPuerperium
dc.subject.proposalSmoking cessation
dc.title.translatedPharmacological interventions for smoking cessation in the pregnant population. A systematic review of systematic reviews
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
dcterms.audience.professionaldevelopmentEstudiantes
dcterms.audience.professionaldevelopmentMaestros


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 InternacionalThis work is licensed under a Creative Commons Reconocimiento-NoComercial 4.0.This document has been deposited by the author (s) under the following certificate of deposit